Elevance Health Q3 Beat and Raised Guidance Signal Resolution of Prior Overhangs

What happened

Elevance Health reported third quarter 2026 results that exceeded expectations, prompting management to raise full-year earnings guidance. The company now expects adjusted diluted EPS of at least $26.753 for 2026, up from the prior floor of $25.50, and projects at least 12% growth in 2027 from that higher base. In the previous analysis (April 2026), the main overhangs were potential CMS sanctions on Medicare Advantage-PD enrollment and communications, and elevated benefit expense ratio pressure. The strong Q3 and guidance raise suggest that those overhangs have been resolved or contained, as management cites 'stronger execution across our diversified portfolio.' However, the press release does not provide granular details on benefit expense ratio, CMS enforcement status, or the DOJ litigation, so investors should verify these in the full earnings release and 10-Q.

Implication

Investors should view the Q3 beat and raised guidance as a positive signal that the CMS sanctions and medical cost trend pressures highlighted in the master report have been addressed. The new 2026 EPS baseline of $26.753 implies a significant upward revision from $25.50, suggesting that management is confident in sustained operational improvement. The projected 12% growth for 2027 from that higher base also indicates that the company expects momentum to continue. However, because the press release is light on specifics, key metrics to monitor include the benefit expense ratio (BER) versus the 90.2% ±50 bps target, the status of CMS enforcement actions, and any updates on the DOJ litigation. If these confirm improvement, the previous WAIT rating should be upgraded, with potential upside to the bull scenario value of $400; conversely, any negative surprises could undermine the rally.

Thesis delta

The thesis shifts from a gated WAIT to a more constructive outlook due to Q3 2026 results beating expectations and management raising 2026 adjusted EPS guidance to at least $26.753, up from $25.50, with 2027 growth of at least 12%. This suggests that prior concerns about CMS sanctions and medical cost pressure have been largely resolved or are under control. The investment case now hinges on confirming that the benefit expense ratio remains within the guided range and that regulatory issues do not resurface, which would support a re-rating toward the bull scenario value of $400.